Maynard Um
-
-
-
-
-
-
-
Cybin Inc. (CYBN) PT Raised to $48 at Guggenheim
-
-
-
-
-
-
-
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
-
-
-
-
-
-
-
Cybin Inc (CYBN) Announces Additional U.S. Patent Supporting CYB004
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cybin Inc. (CYBN)
-
-
-
-
-
-
-
Cybin Inc (CYBN) Expands Clinical Team to Support CYB003 Phase 3 Program
-
-
-
-
404,875 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

